The number of individuals affected by acute kidney injury (AKI) and chronic kidney disease (CKD) is constantly rising. In light of the limited availability of treatment options and their relative inefficacy, cell based therapeutic modalities have been studied. However, not many efforts are put into safety evaluation of such applications. The aim of this study was to review the existing published literature on adverse events reported in studies with genetically modified cells for treatment of kidney disease. A systematic review was conducted by searching PubMed and EMBASE for relevant articles published until June 2018. The search results were screened and relevant articles selected using pre-defined criteria, by two researchers independently. After initial screening of 6894 abstracts, a total number of 97 preclinical studies was finally included for full assessment. Of these, 61 (63%) presented an inappropriate study design for the evaluation of safety parameters. Only 4 studies (4%) had the optimal study design, while 32 (33%) showed sub-optimal study design with either direct or indirect evidence of adverse events. The high heterogeneity of studies included regarding cell type and number, genetic modification, administration route, and kidney disease model applied, combined with the consistent lack of appropriate control groups, makes a reliable safety evaluation of kidney cell-based therapies impossible. Only a limited number of relevant studies included looked into essential safety-related outcomes, such as inflammatory (48%), tumorigenic and teratogenic potential (12%), cell biodistribution (82%), microbiological safety with respect to microorganism contamination and latent viruses' reactivation (1%), as well as overall well-being and animal survival (19%). In conclusion, for benign cell-based therapies, well-designed pre-clinical studies, including all control groups required and good manufacturing processes securing safety, need to be done early in development. Preferably, this should be performed side by side with efficacy evaluation and according to the official guidelines of leading health organizations.
Introduction
Renal insufficiency represents an important health problem and there is a great need for development of new treatment options that could improve quality of life of kidney patients, but also reduce the global social and economic burden on the healthcare system (Levey et al., 2007) . More awareness needs to be raised for prevention of acute kidney injury (AKI) (Lewington, Cerda, & Mehta, 2013) to reduce the mortality and the risk of developing chronic kidney disease (CKD). Also, more effort has to be put into improving the treatment of CKD itself and its progression towards end stage renal disease (ESRD) (Hill et al., 2016; Levey & Coresh, 2012) . For ESRD, the preferred treatment option is kidney transplantation, but application is limited by donor organ shortage. Moreover, kidney transplantation is not an ideal treatment due to complications of immunosuppressive therapy. Consequently, patients with advanced age and those with extensive comorbidity are not eligible for transplantation. Therefore, many patients with ESRD are dependent on treatment with hemodialysis (Ortiz, et al., 2014) . Despite many technological developments and advancements introduced in the field of dialysis in the past few decades, noticeable improvements regarding clinical outcomes, in particular patient survival, are very limited (Lameire, Van Biesen, & Vanholder, 2009) . This is partly explained by the fact that dialysis does not efficiently remove metabolic waste products, leading to their accumulation. These so called uremic toxins have been associated with the development of other co-morbidities over time, especially cardiovascular disease, which remains the main cause of death within ESRD populations (Go, Chertow, Fan, McCulloch, & Hsu, 2004; Vanholder et al., 2008; Weiner et al., 2012) . In addition, the treatment sessions are cumbersome for patients, reducing noticeably their quality of life (Jaar, Chang, & Plantinga, 2013; Jhamb, Weisbord, Steel, & Unruh, 2008) , further indicating the need for alternative treatment strategies.
Tissue engineering and regenerative medicine embody extremely promising innovative strategies that could improve or replace functions of damaged organs, including the kidney, or even repair and regenerate them (Zambon et al., 2014) . One of the recent developments in the field of tissue engineering includes the bioartificial kidney, comprised of viable epithelial cells of either allogeneic or xenogeneic origin, to make use of their transport machinery for a more efficient excretion of waste molecules Humes, Buffington, MacKay, Funke, & Weitzel, 1999; Jansen et al., 2016; Takahashi et al., 2013) . On the other hand, regenerative medicine related approaches might make use of acellular components, such as synthetic biomaterials and scaffolds, or decellularized kidneys that would maintain the complex 3D organization of extracellular matrix (ECM), thus allowing the optimal growth and differentiation of cells, in particular stem cells (Bonandrini et al., 2014; Little & Kairath, 2016; Orlando et al., 2013; Zambon et al., 2014) . Alternatively, the stem cells could also be used directly for transplantation, without using scaffold materials, completely relaying on their regenerative capacities, including beneficial paracrine effects (Little & Kairath, 2016) .
The most frequently used cell types for cell-based CKD treatment are mesenchymal stem cells (MSC), bone marrow cells (BMC), endothelial progenitor cells (EPC) and hematopoietic stem cells (HSC) . However, other cells types have also been studied for their potential to treat kidney disease, such as primary kidney cells (Humes, Weitzel, & Fissell, 2004; Takahashi et al., 2013) , cell lines (Kelly, Kluve-Beckerman, Zhang, & Dominguez, 2010) or cells genetically modified to overexpress certain proteins with therapeutic effects, such as insulin-like growth factor 1 (IGF-1) (Imberti et al., 2007) , hepatocyte growth factor (HGF) (Chen et al., 2011) , erythropoietin (EPO) (Kucic et al., 2008) , CXC chemokine receptor type 4 (CXCR4) (Gheisari et al., 2012; N. Liu, Patzak, & Zhang, 2013) , serum amyloid A1 (SAA1) (Kelly et al., 2010; Kelly et al., 2013; Kelly, Zhang, Wang, Zhang, & Dominguez, 2012) , kallikrein (Hagiwara, Shen, Chao, & Chao, 2008) , vascular endothelial growth factor (VEGF) , and bone morphogenetic protein 7 (BMP-7) (Zhen-Qiang et al., 2012) . In addition, recent advances in the field of induced pluripotent stem cells (iPS) as cell-based therapies for various pathologies, make them a very promising clinical approach and a valuable therapeutic tool for kidney failure as well (Takasato et al., 2015; Toyohara et al., 2015) .
In various animal models of CKD, many of these treatment options were shown to be beneficial, as evaluated by improvement of several histological outcomes (glomerulosclerosis and tubular interstitial fibrosis), as well as functional parameters (glomerular filtration rate (GFR), blood pressure, urinary protein, plasma urea, plasma creatinine). Experimental models of CKD included ischemia-reperfusion injury, diabetic nephropathy, subtotal nephrectomy, hypertension or drug induced kidney disease .
Despite these promising findings of cell-based therapy efficacy for CKD and ESRD, most studies have focused primarily on functional readouts and improvement of clinical parameters. An often neglected aspect and concern encountered when developing and improving cell-based therapies, is safety of the clinical application and especially the longterm effects.
Several safety issues related to cell-based therapies should be addressed prior to clinical application (European Medicines Agency, 2008; Food and Drug Administration, 2013) . According to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), among the most relevant issues are immunogenic, immunotoxic and inflammatory effects, especially in case of allogeneic and xenogeneic cells. Furthermore, immortalized or cells modified and transduced with retro-or lentiviral vectors are of particular concern given the possibility of release of vectors or plasmids. In addition, such modifications could significantly affect cell morphology and behavior, strongly associated with transformed phenotype and oncogenic and tumorigenic potential. Presence of microbial agents is another not negligible issue to be taken into consideration when evaluating the safety of a specific cell type for clinical applications. A systematic review of the evidence on safety of genetically modified cells in vivo would provide important information for future studies aiming to assess possible therapeutic effects and safety of cell-based therapies for kidney disease. Since no such synthesis of evidence currently exists, we have performed a systematic review of all published pre-clinical evidence on the safety of immortalized and genetically modified cells in animal models of kidney disease. We investigated a) whether studies using genetically modified cells in animal models of kidney disease were set up to identify adverse outcomes or safety concerns and b) which safety concerns or adverse outcomes were reported.
Analysis

Review protocol and amendments
The review methodology was pre-specified in a review protocol and registered on http://www.syrcle.nl (see also (de Vries et al., 2015) ). We made the following amendments to the protocol: the review has been extended to include all genetically modified cells in addition to immortalized cell lines. The review question therefore is: 'What is the current evidence for the safety of cell therapy using immortalized and genetically modified cells in animal models of kidney disease?'
Literature search
A systematic review was performed of all available studies reporting safety and adverse effects evaluation of cell-based therapies, in particular immortalized and genetically modified cells, in various animal models of kidney disease. A systematic literature search for articles published up to June 2018, was performed in PubMed and EMBASE. The full search strategies are included in Supplementary material S1 and involved the following components: "cell and tissue based therapy", "kidney disease", and "animals". All articles obtained by this search were evaluated by two independent researchers (M.M. being the first reviewer in all cases and K.E.W. or T.K. vd M. being the second reviewer) based on title and abstract, according to predefined inclusion and exclusion criteria. If abstracts were not available, or not informative enough, the full-text article was screened. If full-text articles were not available or accessible, corresponding authors were contacted via e-mail with a request to supply the full text. In case of discrepancies between the two reviewers, a third investigator (R.M.) was involved in the screening and discussion in order to reach a decision regarding inclusion. No language restrictions were applied. If needed, non-English articles were translated by native speaking scientists.
Inclusion and exclusion criteria
Articles were included if they were primary studies presenting unique data on in vivo experiments in which animals were treated with genetically modified cells to treat renal disease, and any outcome related to safety or adverse events was reported.
Articles that met at least one of the following criteria during the title and abstract screening phase were excluded: (1) there was no kidney disease, (2) there was no cell therapy intervention, (3) the study was not performed in animals in vivo, (4) immunodeficient animals were used, or (5) the study was not a primary study. After screening based on title and abstract, all included articles were subjected to full-text screening with additional exclusion criteria: (6) there was no administration of genetically modified or immortalized cells (7) there were no safety related outcomes measured or indicated, or (8) the full-text article could not be obtained.
Data extraction and analysis
The following study characteristics were extracted from all articles included: animal species, strain, age, sex, weight, kidney disease model, induction of kidney disease, cell type used for therapeutic intervention, cell origin, type of genetic modification of cells, number of cells administered, and administration route. Bibliographic data, such as author and year of publication, were also registered. The following outcomes related to safety and adverse effects were extracted: inflammatory and immune related markers (gene and protein cytokine levels, inflammatory cell infiltration), renal fibrosis (interstitial fibrosis, total collagen, gene and protein expression of transforming growth factor beta (TGF-β), alpha-smooth muscle actin (α-SMA), platelet-derived growth factor (PDGF), type I collagen and matrix metalloproteinases), apoptosis (TUNEL, caspase 3 activity and expression, Bax and Bcl2 expression), organ and tissue distribution of cells (kidneys and other distant organs), tumor and teratoma formation, and overall survival of animals.
Assessment of methodological quality
Methodological quality of the included studies was determined using SYRCLE's risk of bias tool (Hooijmans et al., 2014) with addition of reporting items as used in previous studies (Jonker, Menting, Warle, Ritskes-Hoitinga, & Wever, 2016; Wever et al., 2015) . SYRCLE's risk of bias tool, which aims to establish consistency when assessing internal validity of animal intervention studies, covers five important domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and other biases (Hooijmans et al., 2014) . To assess selection bias due to differences in baseline characteristics between groups, we assessed whether groups were of equal strain, sex and weight or age. Risk of detection bias was assessed separately for all outcomes, versus for histological outcomes only. Risk of bias due to selective outcome reporting was not assessed, since none of the included studies referred to a prospectively registered study protocol, which would allow a comparison between predefined and actually reported outcomes.
Results
Due to the high heterogeneity in study characteristics and in reporting of outcomes among all articles included, a meta-analysis was not considered to be sensible. Therefore, a narrative synthesis of available data was performed.
Study selection and characteristics
The electronic search strategy retrieved 1665 articles from PubMed and 5228 articles from EMBASE. On one occasion an author provided a publication that did not appear in the electronic search (1 article via author). Of these, 5682 were unique and evaluated for inclusion based on title and abstract. In total, 531 articles met the inclusion criteria and were screened as full-text. After full-text assessment, 97 studies were included in this systematic review (Fig. 1) .
Study characteristics of all articles included are summarized in Tables 1 and 2 , reporting details of animal and kidney disease models, as well as the cell therapy used, and outcome measures related to safety and adverse events. There was considerable variation in the characteristics of the animals and the renal disease models employed. Fifty studies (51.5%) were performed in rats, forty-one (42.3%) in mice, two (2.1%) in goats, two (2.1%) in rabbits, one (1.0%) in pigs and one (1.0%) in dogs. Regarding the sex of the animals used, fifty-one studies (52.6%) used males, twenty-four (24.7%) used female animals, six (6.2%) used both sexes, while sixteen studies (16.5%) did not specify the sex of animals used. A plethora of renal disease models was used: forty-nine studies (50.5%) used an AKI model (either ischemia-reperfusion (I/R), cisplatin, gentamicin, nephrectomy, or sepsis-induced), twenty-one (21.7%) used a CKD model (either a subtotal nephrectomy or unilateral ureter obstruction (UUO)), seven (7.2%) a glomerulosclerosis model (both Alport syndrome and other models), two (2.1%) cystinosis, five (5.2%) a glomerulonephritis, six (6.2%) a diabetic nephropathy, two (2.1%) a polycystic kidney disease model, one (1.0%) a kidney transplantation model, one (1.0%) adriamycin-induced nephrotic syndrome model, one (1.0%) a radiation nephropathy model, one (1.0%) a mesangial sclerosis model and one (1.0%) study used both AKI and CKD models. Regarding the cell types used, a majority of studies (86; 88.7%) used various types of stem cells (see Table 2 ). Seven studies (7.2%) used primary cells (renal tubular cells, macrophages or endothelial cells) and only four studies (4.1%) used cell lines. The number of cells administered was also variable, with three studies (3.1%) using a cell number in the order of 10 8 , seven (7.2%) in the order of 10 7 , sixty-two (63.9%) in the order of 10 6 , fourteen (14.4%) in the order of 10 5 , two (2.1%) in the order of 10 4 , six (6.2%) used two or more different amounts ranging from 10 3 to 10 7 , while three (3.1%) studies did not specify the number of cells administered.
All articles included were subdivided in one of four categories based on study design, whether appropriate controls were used in order to determine side effects and risk factors, as well as whether such adverse effects were reported explicitly, and characteristics were explained. Description of all categories and categorized articles is shown in Fig. 2a -b. The optimal study design which would allow to determine both the efficacy and safety of a specific type of genetically modified cells is summarized in Fig. 2c .
The majority of studies (63%) did not have appropriate control groups nor did they report any adverse effects related to the cell therapy implemented to treat kidney disease. In 30% of the studies, a suboptimal study design was found, presenting indirect evidence of cell therapy safety, while specifically reporting adverse events during the course of the study. A total of seven studies had the suitable study design allowing the assessment and monitoring of adverse effects. Out of these seven, three studies (3%) applied genetically modified cells in healthy control animals but did not specifically evaluate adverse events, while four (4%) were optimally designed and did monitor and report the side effects and cell therapy-related problems.
Reporting quality and internal validity of studies
The results of the quality assessment are shown in Fig. 3 . Our assessment of reporting of measures to reduce bias and key indicators of study quality (randomization, blinding, sample size calculation and conflict of interest statement) shows that reporting of these was very poor (Fig. 3a) . Out of ninety-seven studies, only thirty-four (35%) reported randomization of the study at any level, and only one (1%) reported the method of randomization used. Forty-three (44%) studies reported blinding of the study at any level, which in all cases concerned blinding of the outcome measure histology only. Only one study reported a sample size calculation. A statement regarding conflict of interest was reported more frequently, i.e. by seventy-six (78%) studies. As a consequence of poor reporting of measures to reduce bias, our assessment of risk of bias in the included studies yielded mostly unclear risks of selection, performance and detection bias (Fig. 3b) . Out of ninety-seven studies, fifty-six (58%) reported sufficient data on baseline characteristics of the animals (strain, sex and weight or age) to assess that these were similar between groups, which suggests a low risk of bias. Regarding attrition bias, fourteen studies (14%) were assessed as high risk of bias due to unexplained drop-outs. In seventy-one studies (73%) the risk of bias was unclear, because the number of drop-outs could not be assessed or the number of animals per group was not clear. Twelve (12%) studies were assessed as low risk of bias because there were no drop-outs, or the reason of death of experimental animals in each group was specified. Regarding other risks of bias, three studies (3%) exhibited high risk of bias because authors were shareholder of a financially involved company without reporting conflict of interest, or authors had patents pending. The remaining studies were assessed as either low risk of bias (72; 74%), because they explicitly reported no conflict of interest and appeared to be free of other risks of bias, or unclear risk of bias because a conflict of interest statement was lacking (22; 23%).
Kidney disease cell therapy-related adverse effects
Several risk factors and side effects of cell therapy that are generally recognized (European Medicines Agency, 2012; Herberts, Kwa, & Hermsen, 2011 ) (schematically shown in Fig. 4) were considered in all included kidney disease animal studies. Most of the risk factors and side effects considered were related to stem cell-based therapies, given the fact that the majority of studies used stem cells. Nonetheless, the information derived can be easily extrapolated to studies with other cell types, especially genetically modified cells. However, the description of various risk factors, including immunogenicity, tumorigenic effects, teratoma formation, biodistribution, microbial contaminations and overall well-being and survival, varied between studies depending on the cell type or genetic manipulation of the cells. Here, we discuss in more detail their relevance in perspective of the cells used in the selected articles. 
Immunogenicity, cell rejection and tissue damage
Considering cell source and their potential immunogenic effect, all studies were evaluated for cell origin used for kidney disease treatment. The data obtained show that two studies used autologous cell transplantation, twelve used xenogeneic cells, eighty-two studies described the use of allogeneic cells, while one study did not report the origin of cells used. Reported parameters that were taken into account for possible assessment of inflammatory and immunogenic effects were predominantly cytokine expression and release, as well as inflammatory cell infiltration. In total, forty-seven studies were examined and showed at least one of the following outcomes: mRNA or protein levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 17 (IL-17), interleukin 10 (IL-10), interleukin 1 alpha (IL-1α), interleukin 1 beta (IL-1β), monocyte chemoattractant protein 1 (MCP-1), interferon gamma (IFN-γ), or infiltration of leukocytes and ED-1 positive cells. Furthermore, forty studies evaluated the presence of fibrotic markers such as mRNA or protein levels of TGF-β, α-SMA, PDGF, type I collagen and matrix metalloproteinases (MMP 2 and 9), or the extent of fibrotic tissue damage by trichrome periodic acid-Schiff or Sirius Red staining.
Similar findings were observed in case of apoptosis, which was considered as a possible indicator of cell rejection, as suggested previously (Cristobal et al., 2010; Krams et al., 1995) . In total, thirty-two studies reported at least some of the apoptosis-related markers, such as caspase 3 expression, DNA fragmentation (TUNEL staining), Bax and Bcl2 expression. However, all of these studies were focused on reporting the protective effect on kidney tissue damage in terms of reduced number of apoptotic tubular cells, rather than possible adverse effects of cell therapy. As discussed in later sections, several studies evaluated biodistribution and specifically persistence of cells in kidneys, which could be suggestive of cell survival or rejection following administration.
Tumorigenicity, oncogenicity and teratoma formation
Another important risk factor for cell-based therapies is the risk of tumorigenic and oncogenic effects, as well as teratoma formation. Overall, twelve studies assessed teratoma, tumor or other malignant occurrences (Table 3 ). The study by Caldas et al. (2017) , in which iPS cells were used to treat subtotal nephrectomy-induced CKD in rats, showed that iPS cells induced formation of malignant tumors histologically resembling Wilms' tumor in 63% of the cases. Kinomura et al. (2008) , who adopted Lac-Z transfected S3 segment-derived proximal tubule cells (rKS56), stated the tumorigenicity related findings indirectly (T*; Table 2 ) by referring to a previous study performed in nude mice, which suggested the absence of a tumor cell phenotype (Kitamura et al., 2005) . However, according to the karyotype analysis, they found that rkS56 cells employed as cell therapy were nearly triploid regardless of LacZ transfection, and this could represent a risk of tumorigenesis (Giam & Rancati, 2015; Weaver & Cleveland, 2006) . The study by Chen et al. (2011) assessed tumorigenic effect of human umbilical cord-derived mesenchymal stem cells (hucMSC) that were adenovirally-transduced with hepatocyte growth factor (HGF) and green fluorescent protein (GFP), in BALB/c nude mice instead of in the Table 3 ).
Fig. 2.
Articles categorization based on suitability of study design and animal experimental set-up for determination of cell therapy risks and adverse events. Category 1 = Optimal study design (genetically manipulated and wild type cells administered in healthy control animals reporting adverse effects; Category 2 = Sub-optimal study design (genetically manipulated cells administered in healthy animals and monitoring for side effects; Category 3 = Sub-optimal study design with indirect evidence of adverse events (genetically manipulated cells administered only in disease animal models) and reporting adverse events; studies indicated as 3-represent those that did not report explicitly adverse events, even though outcomes kidney disease animal model. Their results indicated the absence of tumor formation in nude mice during a three-months observation period. Moreover, several other studies reported that tumor generation following cell administration into kidney disease animal models was not observed. For instance, Togel, Cohen et al., (2009) showed that MSCs generated from human placental alkaline phosphatase (hPAP) transgenic F344 rats did not give rise to tumors in a Sprague Dawley rat AKI model, while Han et al. (2013) stated that there was no teratoma formation in kidneys of AKI C57BL/6 mice 6 weeks after injection of mouse adult renal progenitor cells derived from C57BL/6-GFP transgenic mice. Similarly, Li et al. (2012)) did not find any presence of teratoma in kidneys of mice with renal ischemic injury up to 6 months following injection of mouse hematopoietic stem and progenitor cells derived from transgenic CreKsp:R26R-EYFP mice and induced to differentiate into cells resembling renal cell phenotype. Moreover, endothelial progenitor cells transfected with telomerase reverse transcriptase did not cause any malignant changes in a chronic kidney disease setting (Shuai et al., 2012) . Roudkenar et al. (2018) showed that lipocalin transfected MSCs were safe enough with no tumor formation observed even 2 months after administration of the cells in an AKI rat model, while the study by Uchida et al. (2017) showed the same result for GFP-lentivirally-transduced BM-MSCs-derived multilineagedifferentiating stress-enduring (Muse) cells in a mouse model of glomerulosclerosis. Lee et al. (2012) and Harrison et al. (2013) showed in two different animal models of kidney disease that iPS cells reprogrammed with retroviral vectors encoding Oct-4, Sox2, Klf4 and EGFP, and hematopoietic stem and progenitor cells transduced with lentiviral vectors bearing CTNS and EGFP genes, respectively, did not induce tumor formation for the duration of the study. Finally, stated that iPS-derived renal progenitor cells did not give rise to any neoplastic formations during 3 months follow-up in an AKI rat model. Overall, only one of the studies that monitored animals for tumor and teratoma formation showed the undesired effects, while the rest of them reported opposite outcome.
Biodistribution of administered cells
The in vivo fate and biodistribution of genetically modified cells are other important factors related to the safety of a cell-based therapy. The majority of the studies included in this systematic review (80; 82%) evaluated at least some biodistribution-related outcomes, such as trafficking, homing, engraftment, differentiation, survival, or persistence of cells after administration. Of these studies, forty-five (56%) focused only on cell engraftment and survival within kidneys, while thirty-five (44%) evaluated distribution in at least one or more additional organs, such as lung, liver, spleen, lymph nodes, stomach, intestine, muscle, brain, blood, bone marrow or eye. The specific cell type, organ or tissue distribution, cell persistence and outcome are shown in Table 4 .
Contamination with microorganisms or adventitious agents and reactivation of latent viruses
Considering all included studies, only Takahashi et al. (2013) focused on safety issues related to pathogen contaminations. In particular, the study was performed to evaluate the effect of serum-containing medium on lifespan-extended renal proximal tubular epithelial cells function in the bioartificial tubule device (BTD). Namely, cells modified with siRNA for p16
INK4a were cultured either in 0.5% serum-containing renal cell growth medium or serum-free RELAR® medium, based on HFDM-1 synthetic medium for human fibroblasts supplemented with various recombinant hormones and growth factors for renal cell culture.
The results obtained showed that both cells cultured in serumcontaining and in serum-free medium presented almost the same growth rate in terms of population doublings and performed equally in BTD with respect to leakage of creatinine and reabsorption of water, glucose and sodium. In addition, the two types of cells exhibited very similar performance in AKI goats during the 26 h extracorporeal circulation with BTD regarding plasma levels of liver enzymes, renal function parameters, glucose, and electrolytes, as well as mRNA levels of a number of cytokines following 8 h lipopolysaccharide (LPS) challenge of peripheral blood mononuclear cells (PBMC). This study suggests that it is possible to culture cells in pathogen-free conditions for cell therapy purposes. Regarding the possibility of reactivation of latent viruses, none of the studies included in this review addressed this issue.
Animal survival
Of the studies included, eighteen (19%) reported animal survival or mortality rate after cell administration ( Table 2 ; outcome "S"). However, in all cases the main focus and intention was not to evaluate possible negative or detrimental effects of genetically modified cells and administration route, but to determine the beneficial effect of cell therapy on the overall survival in a kidney disease setting.
Discussion
Adequate reporting of measures to reduce bias and other key study quality indicators is crucial to assess risks of bias in primary studies and to determine the quality of a body of evidence. Our assessment indicates that animal studies in the renal regenerative medicine field are no exception to the insufficient reporting of preclinical animal studies in general. Since there is accumulating evidence that absence of measures to reduce bias can severely influence primary study results (Hirst et al., 2014) , this is a matter of concern. Importantly, our review aimed to assess outcomes related to safety, but since 99% of the studies did not report a power calculation, it is impossible to assess whether any of the included studies were sufficiently powered to detect differences in these outcomes. This is a crucial point to take into consideration as it might lead to misinterpretation of the results as well as ethical issues with using inappropriate numbers of animals. For that reason, we strongly suggest to always perform a sample size calculation in animal studies by using either the power analysis, similarly to the methods employed for calculation of sample size in clinical studies, or the method called "resource equation" when several outcomes are measured and complex statistical analyses are needed (Charan & Kantharia, 2013; Faul, Erdfelder, Lang, & Buchner, 2007; Festing & Altman, 2002) . Furthermore, since none of the included studies referred to a prospectively registered study protocol, risk of bias due to selective outcome reporting could not be assessed. Akin to clinical trials, where prospective registration of study protocols is the norm, prospective registration of animal studies can provide vital information to reviewers, readers and meta-researchers on e.g. the study hypothesis, endpoints and sample size calculation, and measures to reduce bias (Jansen of Lorkeers, Doevendans, & Chamuleau, 2014; Kimmelman & Anderson, 2012; Ritskes-Hoitinga & Wever, 2018) . We therefore recommend prospective registration on e.g. preclinicaltrials.eu or Open Science Framework, and make a plea for the use of reporting guidelines such as ARRIVE and GSPC (Hooijmans, Leenaars, & Ritskes-Hoitinga, 2010; Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) . Of note, these do not specify how detailed the reporting of measures to reduce bias should be. The guidance notes provided with SYRCLE's risk of bias tool (Hooijmans et al., 2014) offers many examples of how to report relevant to side effects were present; Category 4 = Inappropriate study design (genetically manipulated cells administered in disease animal models not reporting adverse events or relative outcome measurements). A) List of included studies categorized as mentioned; B) Percentages of studies divided over 4 categories. C) Representation of an ideal study design in which both wild-type and genetically modified cells are used in healthy control animals and in animals with kidney disease. Such a study design would allow to determine both the efficacy and safety of a given type of genetically modified cells in certain model of renal disease.
measures to reduce various forms of bias in various stages of an animal experiment.
When considering immunogenicity-related risk factors, it could be expected that allogeneic and xenogeneic cells undergo rejection, thus compromising cell therapeutic activity, or even elicit undesired inflammatory and/or immune responses. This is especially related to the expression of highly polymorphic major histocompatibility complex antigens (MHC), as extensively studied and demonstrated in the solid organ transplantation field (Ingulli, 2010) . Besides cell origin, which was reported by all studies included, several other parameters that might influence immunogenicity should be considered, including the administration site, the need for multiple exposures or administrations, the effect of disease on the immune system, as well as the maturation status of (stem) cells (Sharpe, Morton, & Rossi, 2012) . It has been reported that some cells, such as embryonic stem cells (ESCs), although immunologically immature because they lack MHC class II molecules expression are not completely resistant to immune rejection (Drukker, 2008; Drukker et al., 2006; Li et al., 2004; Liu, Li, Fu, & Xu, 2017) . In addition, most parameters related to immune and inflammatory responses reported by studies included in this review were obtained as an indication of efficacy of cell therapy and attenuation of kidney disease with beneficial anti-inflammatory effects, rather than as a safety evaluation of the cell therapy. Moreover, none of the studies examined systematically the expression of immune related antigens such as MHC Class I and II molecules or other co-stimulatory factors involved in immune system activation. From the observed data, it is not possible to infer any relevant conclusion concerning inflammatory and immune responses induced by specific cell types in kidney disease animal models, considering that there were no healthy or sham-operated animals treated with genetically modified cells and that the population of included studies was highly heterogeneous, especially in terms of animal species and renal disease models used, as well as specific cell type and their mode of application. In addition, in many cases mRNA or protein levels of pro-inflammatory mediators were assessed in peripheral blood or in kidney tissue lysates without discriminating the origin and localization of the inflammatory response within kidneys (glomerular or tubular injures), further hampering the interpretation of possible adverse effects.
Considering that fibrosis is a good indicator of tissue damage it could represent a valid marker for inflammatory response related safety aspects as well. However, fibrotic markers reported by included studies, similarly to inflammatory markers, were almost exclusively addressed for therapeutic goals of cell therapy and to evaluate the impact on renal fibrosis progression.
Furthermore, none of the included studies that reported any of the apoptosis-related markers had the optimal study design, nor determined the apoptosis status of administered cells, offering inconclusive results regarding cell persistence.
Tumorigenic and teratogenic effects of cell therapy are mostly due to the differentiation status of cells, or genetic manipulation and continuous cell culture that can lead to genetic aberrations and genomic alterations associated with cancer and tumor development (Laurent et al., 2011; Mayshar et al., 2010; Zhang et al., 2006) . Even though almost all studies included in this review that monitored for tumor and teratoma formation reported promising findings and the absence of tumorigenic effects, one study showed that iPS cells were able to induce nephroblastoma formation in a CKD animal model (Caldas et al., 2017) . This clearly indicates that genetically manipulated cells and especially stem cells could have negative consequences in cell-based therapeutic approaches. Therefore, when using genetically modified cells, it is essential to evaluate genetic stability of the cells as this can be significantly compromised. Not only genetic modifications, such as transfection and transduction, but also the use of cells derived from transgenic donors and the regular expansion and culture of cells, can be associated with the introduction of chromosomal aberrations and, thus, increase the risk of tumorigenicity in recipients (Rebuzzini, Zuccotti, Redi, & Garagna, 2015; Solomon, Borrow, & Goddard, 1991) . Unfortunately, almost none of the studies included contained a karyotype analysis or other assessment of genetic stability, despite dealing with genetically modified cells or cells derived from transgenic animals. However, it should be recognized that we excluded studies using immunodeficient animals, such as severe combined immunodeficient (SCID) Fig. 4 . Possible risk factors and adverse events related to cell administration for therapeutic purposes. Kitamura et al., 2005: No tumor formation observed in nude mice during 13 months follow-up Lee et al., 2012 Rat iPS No tumor formation observed during 6 months follow-up Li et al., 2012 Mouse HSPCs (Lin-) No teratoma formation observed during 6 months follow-up Rat iPS-derived RPCs No tumor formation observed during 3 months follow-up Roudkenar et al., 2017 Rat MSCs No tumor formation observed during 2 months follow-up Shuai et al., 2012 Rat EPCs No malignant changes observed during 3 months follow-up Togel, Cohen, et al., 2009 Rat 
Cells were present in kidneys up to 14 days after administration.
Ferenbach et al., 2010
Macrophages Kidney, Liver, Spleen, Lung
Fluorescence (PKH26, cell membrane labeling) 24 h after injection high cell densities were identified in the spleen and liver, low cell densities were present in kidney and lung. After injection cells were mainly present in blood and lungs. Cells were present in all organs at day 4 post-injection, with decreased number in lungs. By day 7 after administration cells were almost disappear in all organs. Gao et al., 2012 ADMSCs Kidney BLI (D-luciferase) Cells highly present at day 1. Lower number of cells found at day 14. At day 21 cells were undetectable. Geng et al., 2014 MSCs Muscle, lung, kidney Fluorescence (RFP) 24 h after administration cells were detected in the lung and gastrocnemius muscle, but not in injured kidneys. Gheisari et al., 2012 MSCs Kidney, Lung Flow cytometry (CellTracker Green), Fluorescence (GFP) 36 h post-injection cells were present only in lungs but not in kidneys.
Golle et al., 2017 BMDCs Kidney, heart Fluorescence (GFP) Cells were not detected neither in the heart nor in kidney tissue 2 weeks after administration. Gregorini et al., 2016 MSCs Kidney Fluorescence (GFP) At day 1 post-injection, few cells were detected kidneys mostly located in glomeruli, tubules and interstitium. Guiteras et al., 2017 RAW 264.7 macrophages (cell line)
Whole body (liver, spleen, kidney, lung, heart, bowel, bladder)
Fluorescence (VT-680, intracellular staining)
At 48 h after administration cells were predominantly present in liver and to a lower extent in kidneys and spleen. At day 4 post-injection cells were predominantly present in peritubular areas in kidneys. Jia et al., 2016 BM-MSCs Kidney Fluorescence (GFP) Cells were detectable in kidneys 8 weeks after administration. Katsuoka et al., 2015 MSCs Kidney, heart, brain, lung BLI (D-luciferase) Cells delivered intra-arterially were highly present in kidneys and lower body at day 1 post-injection. In case of the tail vein administration, majority of the cells were detected in the lungs 1 day after administration. Kelley et al., 2013 (continued on next page) mice, which are usually preferred for tumor xenograft evaluation. This was done because it was considered unjustified to combine data from immunodeficient and immunocompetent animals in one data synthesis. Moreover, a kidney disease model in immunodeficient animals does not precisely reflect the genuine pathophysiology.
One of the main biodistribution-related concerns is the undesired migration of cells to non-target organs and tissues, which could cause a risk of developing a local inflammatory response, or neoplasm formation. It has been reported previously that the number of cells reaching desired tissues and organs can be very low (as minimal as 1%) due to the fact that the cells remain trapped within the lungs due to their size and high abundance of surface adhesion molecules, especially in the case of an intravenous administration route (Ankrum & Karp, 2010; Schrepfer et al., 2007) . Therefore, monitoring cell distribution and migration in the body is of crucial importance when assessing safety aspects of cell-based therapies.
Even though many studies included in this review reported biodistribution-related outcomes it is difficult to assess the overall biodistribution of genetically modified cells in kidney disease animal models due to large differences between studies in terms of cell type, administration route, number of cells, time point, and method implemented to trace cell fate after administration as well as kidney disease model applied. However, most studies included reported that cells could reach the kidney and survive for a variable period of time, ranging from 24 h up to one year. Also, all studies that evaluated distribution in organs other than the kidney mentioned cell accumulation in highly vascularized organs, such as spleen, liver and especially lungs. The study by Togel, Yang, Zhang, Hu, and Westenfelder (2008) focused exclusively on monitoring distribution of MSCs in a mouse model of AKI, using bioluminescence imaging (BLI). They showed that following intra-arterial injection in injured mice, cells tended to accumulate in areas corresponding to kidneys, while in healthy mice cells were distributed throughout the whole body, with eventual accumulation in the lungs. On the other hand, intravenous injection of cells led to a predominant and immediate cell accumulation in the lungs both in healthy and AKI mice. This implies that the concern of causing respiratory and hemodynamic complications due to capillary clogging is paramount, especially in case of intravenous injections. Nonetheless, more than 50% of the biodistribution-relevant studies (Table 2 ) adopted the intravenous administration route for cell delivery. In addition, due to a low rate of retention and limited cell survival, large numbers of cells may be needed to achieve therapeutic effects, which would further increase the risk of pulmonary emboli. Besides this undesired effect of cell distribution on efficacy, engraftment of cells in non-target tissues might also be responsible for unwanted negative effects of cell therapies. For instance, different local environments could influence cell behavior and biological properties, thus potentially favoring harmful effects related to differentiation, especially if stem cells are used (Breitbach et al., 2007) . However, none of the included studies reported differentiation issues. Nevertheless, in light of the evidence presented, biodistributionrelated effects should not be underestimated, but carefully and extensively evaluated, especially in terms of mode and site of administration, cell number and type, as well as methodologies employed for cell tracking and detection. The risk of transmission of pathogens, such as bacteria, viruses, fungi or prions, is another important, yet not sufficiently investigated safety concern of cells and tissue xenografts and allografts (Fishman, Greenwald, & Grossi, 2012; Greenwald, Kuehnert, & Fishman, 2012) . This cannot be neglected, especially if the cells intended for use are of non-autologous origin and are genetically modified, cultured and expanded in vitro. Several studies have already described the undesired transmission of pathogens following cell transplantation (Kainer et al., 2004; Tugwell et al., 2005) . Moreover, animal-derived products commonly used for the isolation, culture and propagation of cells, such as fetal calf or bovine serum, represent an additional risk of transfer of contaminants. In fact, due to its method of preparation, fetal bovine serum might be contaminated with mycoplasma, viruses, prions, or endotoxins, thus transmitting diseases. It also contains various biomolecules, such as non-human sialic acid, that could have xeno-immunogenic effects in hosts (Chieregato et al., 2011; Herberts et al., 2011; Jin, Xu, Champion, & Kruth, 2015; van der Valk et al., 2004; van der Valk et al., 2010) . Therefore, in order to avoid ethical issues and controversial procedures involved in harvesting serum from bovine fetuses, and to ensure animal and pathogen-free conditions of cell culture for safer tissue engineering and cell therapy applications, alternatives for fetal bovine serum are highly desired.
Moreover, the possibility of reactivation of latent viruses, such as cytomegalovirus, herpes zoster or Epstein-Barr virus, with the production of infectious viral particles, is another crucial point to be addressed (European Medicines Agency, 2012), which unfortunately was not addressed in any of the included studies. However, we are aware that this aspect of safety is highly linked to the immunosuppressive therapy that might be required when allogeneic cells are applied, and that it can be more relevant in the clinical rather than the preclinical setting.
As mentioned, the experimental design of evaluated studies was often inappropriate for evaluation of the risks associated with cell administration. Even if the main goal of the studies was to assess a therapeutic effect, we believe that additional test groups could have been included to evaluate safety. Notably, the most frequently missing animal group was a control group (e.g. healthy or sham operated animals) in which the same cells were used as in the diseased group. In case of treatment with genetically modified cells, an additional control group of animals treated with wild type cells could also provide valuable information regarding the effect of cell therapy on overall animal well-being. For instance, considering animal survival, it would have been of great value if the studies reporting that outcome had the appropriate control groups, which could give a fair indication of cell therapy effect on survival, without confounding variables such as kidney disease itself. In that regard, most of the included studies that reported any results on animal survival, had a healthy or sham operated control group, depending on the kidney disease model, a vehicle (such as PBS) treated group, and a group treated with genetically modified cells for therapeutic purposes. On rare occasions a group of animals with kidney disease treated with wild type cells, as a control for the group injected with genetically modified cells was included as well. Nonetheless, in the absence of a healthy or sham operated control group treated with genetically modified cells alone, the potential adverse effects of cell therapy on animal survival were difficult to evaluate.
Besides, the studies included in this review are marked by high heterogeneity, especially in terms of the chosen cell type, cell number, route of administration, and, to some extent, cell source. In fact, cell numbers applied across all these studies were in the range of 10 3 -10 8 (Table 2 ). This clearly indicates that the cell number required for optimal therapeutic results is not clear. Higher cell numbers might imply higher risk of developing certain side effects, such as lung obstruction (Schrepfer et al., 2007) , but this also depends on the animal model and route of administration chosen, as reported previously (Togel et al., 2008) . For that reason, a careful examination of cell biodistribution in animal experiments should be performed to determine the effectiveness and safety of a given cell type.
Another important issue is to ascertain the purity of a cell population that is intended for therapeutic use, even more so when cells underwent genetic modifications. With that in mind, the differentiation status of cells should be determined, by examining specific cell type markers and when possible cell specific functions, in order to avoid the undesired tumorigenic risks due to residual undifferentiated cells (Goldring et al., 2011) . When poorly differentiated cells, or even stem cells, such as embryonic stem cells are used, the tumorigenic and teratogenic effects should be evaluated carefully (Blum & Benvenisty, 2008) .
The determination of cell culture purity is also necessary to evaluate the genetic changes that can occur in culture over time, or are a consequence of various genetic manipulations, such as transfection or transduction used to enhance cell function. Karyotype analysis should suffice to determine any significant chromosomal aberrations that might render the cell product unreliable for use, either from the functional point of view or based on cancer risk.
Moreover, when possible, cells should be tested in animal studies at higher passage numbers, usually beyond the routine use, to ensure the safety related to tumorigenicity and immunogenicity, as already suggested ("WHO Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks,", 2010). When using allogeneic or xenogeneic cells, it is extremely important to characterize cells for their immunogenic potential by assessing expression of immune related molecules and antigens, but also by evaluating cells persisting at the site of transplantation to check for cell survival, inflammatory cell infiltration, T cell activation, and cytokine and antibody levels, as indicators of graft rejection and immune system activation (Lee et al., 2014; Lefaucheur et al., 2013; Oliveira, Chagastelles, Sesterheim, & Pranke, 2017; Terasaki & Cai, 2005) . In case of genetically modified cells, major attention should be given to the expression of transgenes, used either for improving cell function or for cell tracking, since the particular gene products can be immunogenic, as was shown for GFP (Ansari et al., 2016) .
Finally, manufacturing processes of cells and cell-based therapies does not provide any viral removal or inactivation and sterilization. Considering that most cells are cultured and expanded in fetal bovine serum-containing growth media, continuous testing for microorganisms should be performed to maintain microbial safety of cell based therapeutic products (Herberts et al., 2011) . In addition to ensuring microbial safety, use of serum-free culture media could help standardize the cell expansion and manufacturing procedures that are subject to serum batch-to-batch variations (3Rs-Centre, 2018; Jochems, van der Valk, Stafleu, & Baumans, 2002; van der Valk et al., 2004; van der Valk et al., 2010; Wessman & Levings, 1999) .
Even though there are several official guidelines (European Medicines Agency, 2008 Agency, , 2012 Food and Drug Administration, 2013 ; "WHO Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks,", 2010) for safety assessment of cell therapies and medicinal products based on cells and tissues, poor preclinical practice makes it difficult for regulatory agencies to establish new or improve currently existing guidelines and recommendations for safety evaluation. Overall, better design and execution of preclinical studies could drastically improve the safety evaluation of genetically modified cell therapy in kidney disease.
Conclusions
We identified ninety-seven studies describing the use and efficacy of genetically modified cells for the treatment of AKI and CKD in animals. However, only seven of these studies (7%) assessed the safety aspects of such therapies in a sufficient manner. Based on the current findings and observations it seems that most cell types employed for kidney disease treatment do not carry significant risk factors and side effects. However, given that most of the studies did not have the optimal design, with 63% designed poorly or inappropriately, and that they were highly heterogeneous with respect to animal species, disease model and cell therapy, it is rather challenging to get a general overview on safety aspects of cell-based therapies. Furthermore, reporting of measures to reduce bias and key study quality indicators was poor in nearly all studies, rendering all studies at unclear risk of bias, which decreases our confidence in the results. Hence, we encourage further research with welldesigned preclinical studies according to the guidelines and recommendations, in order to better define adverse events potentially involved in kidney cell therapy. The most relevant safety-related outcomes are those regarding the purity, biodistribution and immunotoxic effects, as well as the tumorigenic potential related to genetic modifications, genomic instability and differentiation level of cells. Finally, we would like to extend the importance of well-designed and performed preclinical studies for cell-based therapies on other fields as well, such as heart, pulmonary, gastrointestinal, liver and other diseases and that it is worth sounding an alarm bell on the current style of scientific papers describing the use of animal models.
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